See more : Mangalam Global Enterprise Limited (MGEL.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Provention Bio, Inc. (PRVB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Provention Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Cliq Digital AG (CLQDF) Income Statement Analysis – Financial Results
- Splitit Payments Ltd (STTTF) Income Statement Analysis – Financial Results
- Sanghvi Movers Limited (SANGHVIMOV.BO) Income Statement Analysis – Financial Results
- Insimbi Industrial Holdings Limited (ISB.JO) Income Statement Analysis – Financial Results
- Manolete Partners Plc (MANOF) Income Statement Analysis – Financial Results
Provention Bio, Inc. (PRVB)
About Provention Bio, Inc.
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 12.90M | 1.40M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 512.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 12.38M | 1.40M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 96.03% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 75.80M | 69.63M | 66.36M | 36.36M | 22.65M | 7.68M |
| General & Administrative | 64.11M | 47.35M | 33.33M | 8.01M | 4.17M | 1.46M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 64.11M | 47.35M | 33.33M | 8.01M | 4.17M | 1.46M |
| Other Expenses | 627.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 140.54M | 116.97M | 99.69M | 44.37M | 26.81M | 9.14M |
| Cost & Expenses | 141.06M | 116.97M | 99.69M | 44.37M | 26.81M | 9.14M |
| Interest Income | 2.24M | 146.00K | 583.00K | 1.09M | 669.00K | 131.50K |
| Interest Expense | 1.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.47M | 387.00K | 33.00K | -16.00K | 149.00K | 6.50K |
| EBITDA | -124.69M | -115.58M | -99.69M | -44.37M | -26.67M | -9.13M |
| EBITDA Ratio | -966.98% | -8,285.16% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -128.16M | -115.58M | -99.69M | -44.37M | -26.81M | -9.14M |
| Operating Income Ratio | -993.88% | -8,285.16% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.20M | 146.00K | 583.00K | 1.09M | 149.00K | 6.50K |
| Income Before Tax | -126.96M | -115.43M | -99.10M | -43.29M | -26.67M | -9.13M |
| Income Before Tax Ratio | -984.54% | -8,274.70% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -13.39M | -1.00M | -523.00K | -1.09M | -187.00K | -131.50K |
| Net Income | -113.57M | -114.43M | -98.58M | -42.20M | -26.48M | -9.13M |
| Net Income Ratio | -880.69% | -8,203.01% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.52 | -1.81 | -1.88 | -1.04 | -1.18 | -0.27 |
| EPS Diluted | -1.52 | -1.81 | -1.88 | -1.04 | -1.18 | -0.27 |
| Weighted Avg Shares Out | 74.72M | 63.10M | 52.46M | 40.75M | 22.44M | 33.88M |
| Weighted Avg Shares Out (Dil) | 74.72M | 63.10M | 52.46M | 40.75M | 22.44M | 33.88M |
Provention Bio gets FDA approval for treatment that can delay onset of Type 1 diabetes
TZIELD™ (teplizumab-mzwv) approved by FDA as the first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D
Provention Bio, Inc. (PRVB) Q3 2022 Earnings Call Transcript
Why Is Provention Biosciences (PRVB) Stock Up 25% Today?
Provention Bio, Inc. (PRVB) Reports Q3 Loss, Misses Revenue Estimates
Provention Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
Provention (PRVB) Up on Deal With Sanofi for Diabetes Drug
Strength Seen in Provention Bio, Inc. (PRVB): Can Its 25.7% Jump Turn into More Strength?
2 Stocks Jumping in Thursday's Premarket Trading
Sanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes
Source: https://incomestatements.info
Category: Stock Reports